Christophe Courtine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christophe Courtine has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Travis P. Schrank
Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, NC 27599, USA
23 shared publications - Aditi Kothari
Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, North Carolina
21 shared publications - Aditi Kulkarni
University of North Carolina at Chapel Hill 14 Chapel Hill, NC
21 shared publications - Andrew Sewell
Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, North Carolina
21 shared publications - Barbara Burtness
Yale School of Medicine and Yale Cancer Center New Haven Connecticut USA
21 shared publications - Bart Singer
Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, North Carolina
21 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 6. Survival Plot. Prognostic Value of NanoString NAC Classifier Measurements. In Figure 4, PFS was shown for (E) all patients and (F) de-escalation candidates in UNC and E1308 cohorts (non-smoker,
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 6. Survival Plot. Prognostic Value of NanoString NAC Classifier Measurements. In Figure 4, PFS was shown for (E) all patients and (F) de-escalation candidates in UNC and E1308 cohorts (non-smoker,
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 5. NF-κB pathway mutations are found in cases with high NF-κB scores. A) NanoString NF-κB expression scores and NF-κB pathway mutational data from UNC cohort where both metrics were available. B) Non-linear least squares fit of mono-exponential function relating NanoString and RNAseq data. This fit was used to transpose the threshold defined by NanoString to the RNAseq data, where 3 more cases were available.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 5. NF-κB pathway mutations are found in cases with high NF-κB scores. A) NanoString NF-κB expression scores and NF-κB pathway mutational data from UNC cohort where both metrics were available. B) Non-linear least squares fit of mono-exponential function relating NanoString and RNAseq data. This fit was used to transpose the threshold defined by NanoString to the RNAseq data, where 3 more cases were available.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Table 1. Association of NF-κB pathway variants with patient clinical features. P-value assessed by χ2 test, except for age (assessed with t-test).
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Table 1. Association of NF-κB pathway variants with patient clinical features. P-value assessed by χ2 test, except for age (assessed with t-test).
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 3. Boxplot of NF- κB values across the three cluster subtypes. By unsupervised consensus clustering and self-organizing map (SOM) approaches, we identified three distinct biological subtypes within HPV-positive HNSCC: Cl1 (immune-related), Cl2 (epithelial-mesenchymal transition [EMT]-related), and Cl3 (proliferation-related). This classification holds prognostic significance, with Cl1 exhibiting the most favorable survival outcomes, Cl2 associated with the poorest prognosis, and Cl3 displaying an intermediate survival rate [Locati, 2019]. In contrast to recent studies that classified HPV-related HNSCC into immune and keratinocyte subtypes, our analysis confirmed the immune-associated subtype while further resolving the keratinocyte group into two distinct clusters with differing biological profiles and prognostic implications. NF-κB signature is significantly activated in Cl1-immune related cluster compared to the other 2 clusters: A) Metanalyisis-HPV267 cohort (1); B) BD2-HPV286 cohort (2).
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 3. Boxplot of NF- κB values across the three cluster subtypes. By unsupervised consensus clustering and self-organizing map (SOM) approaches, we identified three distinct biological subtypes within HPV-positive HNSCC: Cl1 (immune-related), Cl2 (epithelial-mesenchymal transition [EMT]-related), and Cl3 (proliferation-related). This classification holds prognostic significance, with Cl1 exhibiting the most favorable survival outcomes, Cl2 associated with the poorest prognosis, and Cl3 displaying an intermediate survival rate [Locati, 2019]. In contrast to recent studies that classified HPV-related HNSCC into immune and keratinocyte subtypes, our analysis confirmed the immune-associated subtype while further resolving the keratinocyte group into two distinct clusters with differing biological profiles and prognostic implications. NF-κB signature is significantly activated in Cl1-immune related cluster compared to the other 2 clusters: A) Metanalyisis-HPV267 cohort (1); B) BD2-HPV286 cohort (2).
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Table 2. Association of NF-κB high and low groups with clinical parameters in both Metanalysis-HPV267 (1) and BD2-HPV286 (2). P-value assessed by χ2 test, with the exception of age (t-test). Abbreviations: CHT, chemotherapy; RT, radiotherapy.
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Table 2. Association of NF-κB high and low groups with clinical parameters in both Metanalysis-HPV267 (1) and BD2-HPV286 (2). P-value assessed by χ2 test, with the exception of age (t-test). Abbreviations: CHT, chemotherapy; RT, radiotherapy.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Table 4. Association of NF-κB high and low groups with clinical parameters in combined UNC &E1308 cohorts (1) as pictured in Figure 4D-E. P-value assessed by χ2 test, except for age (assessed with t-test).
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Table 4. Association of NF-κB high and low groups with clinical parameters in combined UNC &E1308 cohorts (1) as pictured in Figure 4D-E. P-value assessed by χ2 test, except for age (assessed with t-test).
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 9. Marker genes by cluster using Leiden method.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 9. Marker genes by cluster using Leiden method.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 4. Comprehensive comparison of all gene sets and potential summary metrics for the NF-κB signature using RNAseq from the UNC cohort. UNC Cohort originally presented in Schrank and colleagues PNAS 2023 (1). Correlation plot with scatter and Pearson correlation values. Nano str – the gene signature utilized in the nanostring assay including 232 NF-κB related genes, which are compared to 27 control genes, these genes were identified in our prior publications as outlined below and represent the combination of the PNAS and Onco large gene sets as defined below. Onco small – Top 50 NF-κB related genes identified in prior work using machine learning improved differential expression, prioritized by p-value in Schrank et at, Oncotarget 2022 (2), 49 of which are included (one excluded by probe design) in the NanoString panel. 29 of these genes are also identified as NF-κB related genes with an orthogonal approach in our prior work using WGCNA (1). Onco large – Top 75 NF-κB related genes identified in prior work using machine learning improved differential expression, prioritized by p-value in Schrank et at, Oncotarget 2022 (2), 74 of which are included (one excluded by probe design) in the NanoString panel 45 of these genes are also identified as NF-κB related genes with an orthogonal approach in our prior work using WGCNA (1). Pnas – 203 NF-κB related genes identified in our prior work using WGCNA, a network-based approach in Schrank and colleagues PNAS 2023 (3). Onco only – NF-κB genes identified by differential expression but not by WGCNA. Pnas only – NF-κB genes identified by WGCNA but not by differential expression. Mean – mean expression of signature genes. Median – median expression of signature genes. PCA – sample value of PC1, for PCA performed on signature genes only after expression normalization. ssGSEA – Signature sized normalized enrichment score (NES) calculated by the single sample gene set enrichment method.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 4. Comprehensive comparison of all gene sets and potential summary metrics for the NF-κB signature using RNAseq from the UNC cohort. UNC Cohort originally presented in Schrank and colleagues PNAS 2023 (1). Correlation plot with scatter and Pearson correlation values. Nano str – the gene signature utilized in the nanostring assay including 232 NF-κB related genes, which are compared to 27 control genes, these genes were identified in our prior publications as outlined below and represent the combination of the PNAS and Onco large gene sets as defined below. Onco small – Top 50 NF-κB related genes identified in prior work using machine learning improved differential expression, prioritized by p-value in Schrank et at, Oncotarget 2022 (2), 49 of which are included (one excluded by probe design) in the NanoString panel. 29 of these genes are also identified as NF-κB related genes with an orthogonal approach in our prior work using WGCNA (1). Onco large – Top 75 NF-κB related genes identified in prior work using machine learning improved differential expression, prioritized by p-value in Schrank et at, Oncotarget 2022 (2), 74 of which are included (one excluded by probe design) in the NanoString panel 45 of these genes are also identified as NF-κB related genes with an orthogonal approach in our prior work using WGCNA (1). Pnas – 203 NF-κB related genes identified in our prior work using WGCNA, a network-based approach in Schrank and colleagues PNAS 2023 (3). Onco only – NF-κB genes identified by differential expression but not by WGCNA. Pnas only – NF-κB genes identified by WGCNA but not by differential expression. Mean – mean expression of signature genes. Median – median expression of signature genes. PCA – sample value of PC1, for PCA performed on signature genes only after expression normalization. ssGSEA – Signature sized normalized enrichment score (NES) calculated by the single sample gene set enrichment method.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 6. Survival Plot. Prognostic Value of NanoString NAC Classifier Measurements. In Figure 4, PFS was shown for (E) all patients and (F) de-escalation candidates in UNC and E1308 cohorts (non-smoker,
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 6. Survival Plot. Prognostic Value of NanoString NAC Classifier Measurements. In Figure 4, PFS was shown for (E) all patients and (F) de-escalation candidates in UNC and E1308 cohorts (non-smoker,
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 8A. UMAP dimensional reduction plots with marker gene validating cell type assignments. Marker genes related to epithelial cells, endothelial cells, fibroblasts, mast cells, dendritic cells, and myeloid cells. Supplemental Figure 8B. UMAP dimensional reduction plots with marker gene validating cell type assignments. Marker genes related to natural killer, B, T and cycling cells.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Development of a Clinical Assay to Guide Patient Therapy in HPV-Associated Head and Neck Cancer
Supplemental Figure 8A. UMAP dimensional reduction plots with marker gene validating cell type assignments. Marker genes related to epithelial cells, endothelial cells, fibroblasts, mast cells, dendritic cells, and myeloid cells. Supplemental Figure 8B. UMAP dimensional reduction plots with marker gene validating cell type assignments. Marker genes related to natural killer, B, T and cycling cells.